Physician profile
Jan Roda
NPI 1386619492
$11,546.29
in general payments reported to CMS, 2019-2025
17 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $507 · 2021: $1,290 · 2022: $904 · 2023: $1,786 · 2024: $2,646 · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,329 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,329.17 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,422.16 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,304.60 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,295.54 | 2022-2025 | Caplyta |
| Allergan, INC. | $991.63 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $638.02 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $589.99 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $547.33 | 2021 | |
| Axsome Therapeutics, INC. | $535.46 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $293.23 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $224.97 | 2019 | |
| Bausch Health US, LLC | $186.06 | 2022 | |
| Avanir Pharmaceuticals, INC. | $125.00 | 2019 | |
| Corium, LLC | $123.07 | 2023 | Azstarys |
| Alkermes, INC. | $118.96 | 2024 | Lybalvi |
| Sunovion Pharmaceuticals INC. | $109.60 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $26.07 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.60 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Roda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.